Mankind Pharma

Mankind Pharma Tangible Book Value per Share

The Tangible Book Value per Share of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 237.58 INR. In the previous year, Tangible Book Value per Share was -55.32 INR — a change of -529.45% (higher).

Tangible Book Value per Share

237.58INR

YoY

-529.45%

Last updated:

Tangible Book Value per Share of Mankind Pharma is 2026 237.58 INR. Tangible Book Value per Share of Mankind Pharma was 2025 -55.32 INR. It decreases by -529.45% higher compared to the previous year.

The Mankind Pharma Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2019
67.89 INR
Jan 1, 2020
83.31 INR
Jan 1, 2021
113.44 INR
Jan 1, 2022
103.21 INR
Jan 1, 2023
137.03 INR
Jan 1, 2024
186.04 INR
Jan 1, 2025
-55.32 INR
Jan 1, 2026
237.58 INR
The Mankind Pharma Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
237.58INR-529.45%
-55.32INR-129.74%
186.04INR+35.77%
137.03INR+32.77%
103.21INR-9.02%
113.44INR+36.17%
83.31INR+22.71%
67.89INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mankind Pharma stock

Tangible Book Value per Share of Mankind Pharma is 237.58 INR in 2026.

Tangible Book Value per Share of Mankind Pharma changed from -55.32 INR to 237.58 INR, representing a -529.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Mankind Pharma

All Key Metrics — Mankind Pharma